Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

BACKGROUND: Regorafenib or trifluridine/tipiracil as third-line treatment have limited efficacy in metastatic colorectal cancer (mCRC). METHODS: This Phase 2 trial evaluated the efficacy and safety of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type mCRC patients who a...

全面介紹

Na minha lista:
書目詳細資料
發表在:Br J Cancer
Main Authors: Masuishi, Toshiki, Tsuji, Akihito, Kotaka, Masahito, Nakamura, Masato, Kochi, Mitsugu, Takagane, Akinori, Shimada, Ken, Denda, Tadamichi, Segawa, Yoshihiko, Tanioka, Hiroaki, Hara, Hiroki, Sagawa, Tamotsu, Watanabe, Takanori, Takahashi, Takao, Negoro, Yuji, Manaka, Dai, Fujita, Hideto, Suto, Takeshi, Takeuchi, Masahiro, Ichikawa, Wataru, Fujii, Masashi
格式: Artigo
語言:Inglês
出版: Nature Publishing Group UK 2020
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7652864/
https://ncbi.nlm.nih.gov/pubmed/32863385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01042-w
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍